BC Week In Review | Feb 28, 2019
Financial News

CStone raises $285M in Hong Kong IPO

CStone Pharmaceuticals Co. Ltd. (HKSE:2616) priced its IPO on the Hong Kong stock exchange Feb. 25, raising HK$2.2 billion (US$285 million). The oncology company rose HK$0.86 to HK$12.86 in its first day of trading Feb....
BC Extra | Feb 26, 2019
Financial News

First-day gain for CStone on Hong Kong exchange

CStone Pharmaceuticals Co. Ltd. (HKSE:2616) rose HK$0.86 to HK$12.86 in its first day of trading Tuesday after raising HK$2.2 billion ($285 million) in its IPO. The oncology company priced the offering early Monday near the...
BC Extra | Feb 25, 2019
Financial News

CStone raises $285M in Hong Kong IPO

CStone Pharmaceuticals Co. Ltd. (HKSE:2616) priced its IPO on the Hong Kong stock exchange early Monday, raising HK$2.2 billion (US$285 million). The offering values CStone at HK$11.8 billion (US$1.5 billion). CStone sold 18.6 million shares...
BC Week In Review | Feb 15, 2019
Financial News

CStone could get $1.5B valuation in Hong Kong IPO

CStone Pharmaceuticals Co. Ltd. (Suzhou, China) would be valued at HK$11.8 billion ($1.5 billion) if it prices its Hong Kong IPO at the midpoint of its proposed range. The cancer company plans to sell 186.4...
BC Extra | Feb 14, 2019
Financial News

CStone could get $1.5B valuation in Hong Kong IPO

CStone Pharmaceuticals Co. Ltd. (Suzhou, China) would be valued at HK$11.8 billion ($1.5 billion) if it prices its Hong Kong IPO at the midpoint of its proposed range. The cancer company plans to sell 186.4...
BC Week In Review | Nov 16, 2018
Financial News

CStone lines up for Hong Kong IPO

With an anti-PD-L1 mAb in Phase III testing and cornerstone investors such as WuXi Ventures and Boyu Capital, immuno-oncology company CStone Pharmaceuticals Co. Ltd. (Suzhou, China) proposed to list on the Hong Kong stock exchange...
BC Extra | Nov 12, 2018
Financial News

CStone lines up for Hong Kong IPO

With an anti-PD-L1 mAb in Phase III testing and cornerstone investors such as WuXi Ventures and Boyu Capital, immuno-oncology company CStone Pharmaceuticals Co. Ltd. (Suzhou, China) on Monday proposed to list on the Hong Kong...
BioCentury | Aug 4, 2018
Finance

Hong Kong’s first wave

Having broken the seal on the new biotech chapter of Hong Kong Exchange and Clearing Ltd., the performance of Ascletis Pharma Inc. and the next few companies to go out could determine what happens to...
BC Week In Review | Jun 29, 2018
Company News

China's Everest gets rights to Novartis' FGFR4 inhibitor

C-Bridge-backed Everest Medicines Ltd. (Shanghai, China) gained an exclusive, worldwide license to FGF401 from Novartis AG (NYSE:NVS; SIX:NOVN). The deal marks the second in-licensing of a fibroblast growth factor (FGF) receptor 4 (FGFR4; CD334) inhibitor...
BC Extra | Jun 26, 2018
Company News

China's Everest gets rights to Novartis' FGFR4 inhibitor

C-Bridge-backed Everest Medicines Ltd. (Shanghai, China) gained an exclusive, worldwide license to FGF401 from Novartis AG (NYSE:NVS; SIX:NOVN) on Monday. The deal marks the second in-licensing of a fibroblast growth factor (FGF) receptor 4 (FGFR4;...
Items per page:
1 - 10 of 18